AN INDUSTRY RIPE FOR GROWTH
CBD is available in a variety of forms, from oils to pills to lollipops, in most states, including the more than 30 states that have legalized marijuana. The CBD market is exploding—it’s projected to exceed $22 billion by 2022, according to the “2019 U.S. Cannabis Market Report” from Brightfield Group. That’s up from $591 million in 2018. By comparison, the entire U.S. nutraceuticals industry is expected to reach about $100 billion by 2022, according to Business Wire.
As the market for CBD continues its ultra-rapid growth, how long before non-acute facilities start recommending it? Right now, it’s unclear what percentage of primary care physicians are talking about it or prescribing it to patients. A study showed that 90% of doctors were unprepared to prescribe medical marijuana because they didn’t learn about it in medical school. That same problem—lack of training and reliable information—may be responsible for doctors not recommending CBD.
What is clear is that there’s a lot of interest in the products. A study from March 2019 found that 40% of adults are interested in trying CBD, but they want easier access, more information and a physician’s recommendation before taking it.
“We are seeing many consumers looking to incorporate CBD into their wellness regimen,” says Mike Luce, cofounder of High Yield Insights, which conducted the survey, in a news release. “Consumers previously unfamiliar with CBD are rapidly showing interest. Now that the federal government is finally taking steps to clear up the hazy legal picture, people see CBD as an entry point to the therapeutic benefits of cannabis.”